Fig. 6.

The effects of (S)-crizotinib on osteosarcoma were produced through targeting MTH1 and activating ROS. (a, b) Detection of 8-oxod-GTP incorporation into DNA in MG63 and MNNG/HOS cells treated with DMSO, 5 μmol/l (S)-crizotinib by staining with Cy3-conjugated avidin. (c) Quantification of 8-oxod-GTP incorporation into DNA: bars are mean±SD from three independent experiments. **P<0.01 and ***P<0.001 compared with the DMSO group, Student’s t-test. (d) Quantification of data of intracellular reactive oxygen species by dichlorofluorescin fluorescence in OS cells following exposure to DMSO, 5 μmol/l (S)-crizotinib alone, or combined with 5 mmol/l NAC for 24 h. Bars are mean±SD from three independent experiments. P>0.05, **P<0.01, Student’s t-test. (e) Cell viability determined by the CCK8 assay in OS cells following exposure to DMSO, 5 mmol/l NAC, 5 μmol/l (S)-crizotinib alone, or combined with 5 mmol/l NAC for 72 h. Bars are mean±SD from three independent experiments. **P<0.01 and ***P<0.001, Student’s t-test.